Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12526MR)

This product GTTS-WQ12526MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12526MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1233MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ9595MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ617MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ10647MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ3030MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ10483MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ10384MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ13130MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04360365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW